ABSTRACT: Bovine herpesvirus type 5 (BHV-5) is the causative agent of bovine herpetic encephalitis, a major concern for cattle farming in Brazil and Argentina. We recently developed a differential, gE-negative vaccine (265 gE-), based on a Brazilian BHV-1 strain. The present study was carried out to examine whether such a vaccine would confer protection to BHV-5 infections. It was concluded that the recombinant BHV-1 vaccine tested here is not capable of conferring full protection to BHV-5 challenge.
INTRODUCTION
Bovine herpesvirus type 5 (BHV-5), an alphaherpesvirus, is the causative agent of bovine herpetic encephalitis, 1 a major concern for cattle farming in Brazil and Argentina. 2, 3 Despite the extensive serological cross-reactions between BHV-5 and infectious bovine rhinotracheitis virus 4 (bovine herpesvirus 1; BHV-1), doubt persists on whether BHV-1 vaccines would be able to protect cattle against BHV-5. Previous experiments using conventional BHV-1 vaccines have shown some degree of protection, but the establishment of disease in nonvaccinated controls was not clear. 5 Under field conditions, in the lack of other control measures, it has been a common practice to vaccinate against BHV-1 when outbreaks of BHV-5 are detected. We have recently developed a differential, gE-negative vaccine (265 gE− ), based on a Brazilian BHV-1 strain. 6 The present study was carried out to examine whether such a vaccine would confer protection to BHV-5 infections.
EXPERIMENTAL DESIGN
Eight calves were vaccinated with the recombinant BHV-1 strain 265 gE− [4 calves intranasally (IN); four calves intramuscularly (IM)]; six calves were kept as controls. Thirty-five days later, both groups were challenged with 10 8.8 50% tissue culture infectious doses (TCID 50 ) of the Brazilian BHV-5 wild-type strain EVI 088/ 95. The animals were monitored daily until day 21 postchallenge (pc), when 4 animals from each group were culled. Sixty days later, the remaining calves were submit-FIGURE 1. BHV-5 virus shedding (expressed as log 10): (a) after challenge and (b) upon corticosteroid-induced reactivation. Note that there are no significant differences between intranasally (diamonds) and intramuscularly (squares) BHV-1 vaccinated calves and those included on the nonvaccinated group (circles). In panel a, "days" refers to days postchallenge; in panel b, it refers to days after corticosteroid administration.
ted to corticosteroid administration in order to induce virus reactivation. All laboratory and animal care procedures, such as viral isolation and titration, seroneutralization assays, and corticosteroid-induced reactivation, were performed as described previously. 7 
RESULTS AND DISCUSSION
Calves readily developed antibodies against BHV-1 and cross-reactive neutralizing antibodies against BHV-5; the titers were above 32 at day 35 after vaccination in both IN and IM groups. During acute BHV-5 disease, between days 3 and 11 after infection, mild clinical signs of respiratory disease were evident in both groups of infected calves. In addition, the calves displayed signs of depression of low magnitude. Two calves from the control group were more severely affected and presented pronounced signs of neurological disease (hypersalivation, teeth chewing, recumbency, incoordination, and difficulty in standing) between days 7 and 21 pc, being culled in extremis. On day 21 pc, four of the vaccinated calves and two of the remaining calves from the control group were culled. Postmortem examinations revealed that all calves in both groups had typical BHV-5 lesions in the brain, including foci of malacia and sinking areas on the frontal, parietal, and temporal lobes. Mononuclear meningoencephalitis was a consistent microscopical finding. Upon corticosteroid-induced reactivation, no respiratory or nervous signs were noticed, despite evident virus shedding. Atrophic brain lesions were present in three of the vaccinated calves as well as in two calves from the control group. However, it was not possible to determine whether such lesions were consequent to reactivation or primary infection. No significant differences were observed in BHV-5 virus shedding between previously BHV-1 vaccinated and nonvaccinated calves either in the early phase following challenge or during reactivation (FIG. 1) .
It is concluded that the recombinant BHV-1 vaccine tested here is not capable of conferring full protection to BHV-5 challenge. Under field conditions, in the lack of other control measures, vaccinations have lead practitioners to recommend BHV-1 vaccination in trying to control BHV-5 outbreaks. Clearly, other BHV-1 vaccines, when applied with this purpose, would have to be equally evaluated; otherwise, such indication may be worthless. Future studies shall be conducted in order to evaluate type-specific vaccines to control BHV-5 infections.
